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Abstract 
Thymoquinone is an antioxidant phytochemical that has been shown to inhibit 
neuroinflammation. However, little is known about the potential roles of intracellular 
antioxidant signalling pathways in its anti-inflammatory activity. The objective of this 
study was to elucidate the roles played by activation of the Nrf2/ARE antioxidant 
mechanisms in the anti-inflammatory activity of this compound. Thymoquinone 
inhibited lipopolysaccharide (LPS)-induced neuroinflammation through interference 
with NF-B signalling in BV2 microglia. Thymoquinone also activated Nrf2/ARE 
signalling by increasing nuclear localisation, DNA binding and transcriptional activity 
of Nrf2, as well as increasing protein levels of HO-1 and NQO1. Suppression of Nrf2 
activity through siRNA or with the use of trigonelline resulted in the loss of anti-
inflammatory activity by thymoquinone. Taken together, our studies show that 
thymoquinone inhibits NF-B-dependent neuroinflammation in BV2 microglia, by 
targeting antioxidant pathway involving activation of both Nrf2/ARE. We propose that 
activation of Nrf2/ARE signalling pathway by thymoquinone probably results in 
inhibition of NF-B-mediated neuroinflammation. 
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1. Introduction 
Neuroinflammation is now widely accepted as one of the major hallmarks in the 
pathogenesis of neurodegenerative disorders such as Alzheimer’s disease. 
Microglial cells, which are the resident macrophages of the CNS are known to play 
major roles in neuroinflammation, serving as a first line of immune defence in 
response to stimuli such as infection, traumatic brain injury, and other forms of 
stress. 
NF-B is a transcription factor that binds to DNA and activates gene transcription. 
The activation of NF-B has been shown to be associated with inflammation in 
microglia in the CNS, where it has been found to mediate different responses [1]. 
Several genes are responsive to the transcriptional activity of NF-B and promoting 
neuroinflammation. These include the pro-inflammatory cytokines [2-4], inducible 
nitric oxide synthase (iNOS) [5], cyclooxygenase-2 (COX-2) and microsomal 
prostaglandin E synthase-1 (mPGES-1) [6]. 
Harmful effects of oxidative and nitrosative stress is now known to cause damage to 
the biological system [7]. There is a strong link between oxidative stress and 
inflammation. An unbalanced redox state is known to contribute to the pathogenesis 
of inflammatory conditions, including ageing [8]. Furthermore, it is now widely 
accepted that inflammation triggers the generation of elevated levels of cellular 
reactive oxygen species that cause cellular oxidative damage [9]. On the other hand, 
inflammatory cells respond to oxidative stress by releasing various NF-B-mediated 
pro-inflammatory mediators [10]. Oxidative stress has also been linked to 
neuroinflammation. Accumulating evidence indicates that reactive oxygen species 
(ROS) produced by the microglia have a significant impact on adjacent neurons, as 
well as modulating microglial activity [11]. It has been shown that the activated 
microglia M1 phenotype is associated with elevated levels of NADPH oxidase 
(NOX)-dependent ROS generation [12]. Consequently, oxidative stress is now 
recognised as an important contributor to neuroinflammation, and its resultant 
neuronal damage in neurodegenerative disorders.  
The nuclear erythroid 2 related factor 2 (Nrf2) is a major regulator of endogenous 
defence mechanisms in the body [13]. In the nucleus, Nrf2 binds to the antioxidant 
response element (ARE) DNA sites to initiate the transcription of several 
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cytoprotective genes. Studies have linked the activation of Nrf2 to anti-inflammatory 
activity through mechanisms involving NF-B [13]. For example, Nair et al. (2008) 
have identified NF-B binding sites in the promoter regions of the Nrf2 gene, 
suggesting an interaction between the two transcription factors [14]. Further, 
neuroinflammation and microglia activation in response to LPS have been shown to 
be more pronounced in Nrf2-deficient mice when compared to normal animals [15]. 
Consequently, it would be interesting to establish the contribution of Nrf2 activation 
in the inhibition of neuroinflammation by pharmacological substances. 
Accumulating evidence have suggested that nutritional factors might be important 
modifiable risk factors for AD [19], and can play an important role in delaying its 
onset or halting its progression and to improve cognitive function. Dietary factors that 
have been shown to inhibit neuroinflammation include punicalagin [16], tiliroside [17], 
and naringenin [18].  
Thymoquinone (Figure 1) is the main constituent of the oil obtained from the seeds 
of Nigella sativa (black cumin seed oil), which has been used for medicinal purposes 
for centuries in Asia, Middle East, and Africa. This compound has been shown to 
produce anti-inflammatory [19-22] and antioxidant [23] properties. Previous studies 
have shown that thymoquinone protected dopaminergic neurons against MPP+ and 
rotenone-induced cell death [24], and produced neuroprotective effects in cultured 
rat primary neurons exposed to amyloid β [25, 26]. Studies have also shown that 
thymoquinone inhibited neuroinflammation in mixed glial cells [27] and BV2 microglia 
[28, 29]. 
In this study, we have shown further that thymoquinone inhibits neuroinflammation in 
LPS-stimulated cultured BV2 and rat primary microglia. We have further shown that 
inhibition of neuroinflammation by thymoquinone in BV2 microglia is related to its 
ability to activate both the Nrf2 antioxidant and LKB1/AMPK1 signalling pathways. 
2. Materials and methods 
2.1 Cell culture 
BV2 mouse microglia cell line ICLC ATL03001 (Interlab Cell Line Collection, Banca 
Bilogica e Cell Factory, Italy) were maintained in RPMI1640 medium with 10% fetal 
bovine serum (FBS) (Sigma), 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 
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100 mg/ml streptomycin (Sigma) in a 5% CO2 incubator. Cells were treated with LPS 
(100 ng/ml; from Salmonella typhimurium, Sigma Aldrich). 
Primary mixed glial cell cultures were established from cerebral cortices of postnatal 
day P0-P1 Sprague–Dawley rats. Briefly, forebrains were minced, dissociated and 
collected by centrifugation (1000 × g, 10 min, 4C), re-suspended in DMEM, 
containing 10% foetal calf serum and antibiotics (40 U/mL penicillin and 40 µg/mL 
streptomycin) and cultured on 10 cm cell culture dishes (Falcon, Heidelberg, 
Germany) in 5% CO2 at 37°C. After 12-14 days in vitro, floating microglia were 
harvested from mixed glia cultures and re-seeded into cell culture plates. The next 
day, medium was removed to get rid of non-adherent cell and fresh medium was 
added and after 1 h, cells were used for experiments. Cells were treated with LPS 
(10 ng/ml; from Salmonella typhimurium, Sigma Aldrich). 
2.2 Cell viability assays 
Cultured BV2 or primary rat microglia were incubated with or without LPS (100 ng/ml 
for BV2 or 10 ng/ml for rat primary microglia) in the absence or presence of 
thymoquinone (2.5–10 µM) for 24 h. Thereafter, cells were lysed and supernatants 
collected for LDH assay. LDH levels in supernatants were determined using the 
CytoTox 96® non-radioactive cytotoxicity assay kit (Promega, Southampton), 
according to the manufacturer’s instructions. 
2.3 Determination of TNFα, IL-6, PGE2, and NO production in LPS-activated 
microglia 
BV2 or rat primary microglia were incubated with or without LPS (100 ng/ml or 
10 ng/ml)) in the absence or presence of thymoquinone (2.5–10 µM) for 24 h. After 
stimulation, cell supernatants were collected and centrifuged at 1000 g for 5 min at 
4 C. Release of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) from culture 
supernatants was determined using mouse or rat TNFα, IL-1β and IL-6 ELISA kits 
(Biolegend, UK). Nitrite production was quantified using the Griess assay kit 
(Promega, Southampton, UK), followed by colorimetric measurement at 540 nm. 
PGE2 release was measured in cell supernatants with a commercially available 
enzyme immunoassay (EIA) kit (Arbor Assays, MI, USA), followed by measurement 
at 450 nm, according to the manufacturer’s instructions. 
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2.4 DNA binding assays 
An ELISA-based DNA binding assay (EMSA) was used to investigate the effects of 
thymoquinone on DNA binding of NF-B, as earlier described [30, 31]. BV2 microglia 
were treated with thymoquinone (2.5-10 µM). Thirty minutes later, cells were 
stimulated with LPS (100 ng/ml). One hour later, nuclear extracts were prepared 
using EpiSeeker Nuclear Extraction Kit (Abcam), according to the manufacturer's 
instructions. DNA binding assay was carried on nuclear extracts using the TransAM 
NF-B transcription factor EMSA kit containing immobilised NF-B consensus site (5’ 
GGGACTTTCC-3’) (Activ Motif, Belgium) according the manufacturer’s instructions. 
Briefly, 30 µl of complete binding buffer were added to each well, followed by 20 µg 
nuclear extract samples. The plate was covered and rocked (100 rpm) for 1 h at 
room temperature. This was followed by addition of NF-B antibody (1:1000; 1 h) 
and HRP-conjugated antibody (1:1000; 1 h). Absorbance was read on a Tecan F50 
microplate reader at 450 nm. 
To investigate DNA binding of Nrf2, BV2 microglia were treated with thymoquinone 
(2.5-10 µM). Nuclear extracts were added to 96-well plates on which has been 
immobilised oligonucleotide containing the ARE consensus binding site (5’ 
GTCACAGTGACTCAGCAGAATCTG-3’). Assay procedure was as described for 
NF-B, using an Nrf2 antibody (1:1000; 1 h). 
2.5 Immunofluorescence microscopy 
Immunofluorescence experiments were carried out as described earlier [32]. BV2 
microglia were cultured in 24 well plates. At confluence, cells were pre-treated with 
thymoquinone (2.5-10 µM) 30 min prior to LPS (100 ng/ml) stimulation. At the end of 
the stimulation, cells were fixed with ice-cold 100% methanol for 15 min at -20ºC and 
washed 3 times for 5 min with PBS. Non-specific binding sites were blocked by 
incubating cells in 5% BSA blocking solution (containing 10% horse serum in 1X 
TBS-T) for 60 min at room temperature followed by washing with PBS. Thereafter, 
the cells were incubated with rabbit anti-NF-Bp65 (Santa Cruz; 1:100) antibody 
overnight at 4ºC. Following overnight incubation, cells were washed 3 times with 
PBS and incubated for 2 h in dark with Alexa Fluor 488-conjugated donkey 
anti-rabbit IgG (Life Technologies; 1:500) secondary antibody. Thereafter, cells were 
washed with PBS and counterstained with 4', 6 diamidino-2-phenylindole 
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dihydrochloride (50 nm, DAPI; Invitrogen) for 5 min. After rinsing cells with PBS, 
excess buffer was removed and gold antifade reagent (Invitrogen) was added. All 
staining procedures were performed at room temperature. Representative 
fluorescence images were obtained using EVOS® FLoid® cell imaging station. 
Immunofluorescence was also used to detect nuclear localisation of Nrf2 in BV2 
microglia treated with thymoquinone (2.5-10 µM), using rabbit Nrf2 antibody (Santa 
Cruz; 1:100). 
2.6 Preparation of cytoplasmic and nuclear extracts 
To obtain cytoplasmic extracts following treatments, cells were washed with PBS 
and lysed in 1.3× SDS-containing sample buffer without 1, 4-DTT or bromophenol 
blue containing 100 μM orthovanadate. Nuclear extracts were obtained using a 
commercially available nuclear extraction buffer (Abcam, UK). Following cytoplasmic 
and nuclear extraction, protein concentrations were determined. 
2.7 Immunoblotting 
For Western blotting, 20-40 μg of total protein from each sample was subjected to 
SDS-PAGE under reducing conditions. Proteins were then transferred onto 
polyvinylidene fluoride (PVDF) membranes (Millipore). The membranes were 
blocked for 1 h at room temperature and then incubated overnight at 4°C with 
primary antibodies. Primary antibodies used were rabbit anti-COX-2 (Santa Cruz), 
rabbit anti-iNOS (Santa Cruz), rabbit anti-phospho-IκBα (Santa Cruz), rabbit anti-
phospho-p65 (Cell Signalling), rabbit anti-p65 (Cell Signalling) rabbit anti-acetyl-p65 
(Cell Signalling), rabbit anti-Nrf2 (Santa Cruz), rabbit anti-HO1 (Santa Cruz), rabbit 
anti-NQO1 (Santa Cruz), and rabbit anti-actin (Sigma). Primary antibodies were 
diluted in Tris-buffered saline (TBS), containing 0.1% Tween 20 (TBS-T) and 1 or 5% 
BSA. Membranes were incubated with the primary antibody overnight at 4°C. After 
extensive washing (three times for 15 min each in TBS-T), proteins were detected by 
incubation with Alexa Fluor 680 goat anti-rabbit secondary antibody (1:10000; Life 
Technologies) at room temperature for 1 h. Detection was done using a LICOR 
Odyssey Imager. All Western blot experiments were carried out at least three times. 
2.8 Real-time quantitative PCR 
RNA preparation was done by using RNAspin mini RNA isolation kit (GE Healthcare, 
Freiburg, Germany) and for cDNA synthesis, 1 μg of total RNA was reverse 
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transcribed using M-MLV reverse transcriptase and random hexamers (Biomers, 
Ulm, Germany). The synthesised cDNA was the template for the real-time PCR 
amplification that was carried out by the CFX96 real-time PCR detection system 
(Bio-Rad Laboratories, Inc.) using iQTM SYBRTM Green supermix (Bio-Rad 
Laboratories GmbH, Munich, Germany). Specific primers were designed by using 
Universal Probe Library Assay Design Center (Roche) and were obtained from 
Biomers (Ulm, Germany). Reaction conditions were 3 min at 95 °C, followed by 40 
cycles of 15 s at 95°C, 30 s at 50°C, and 45 s at 72°C, and every cycle was followed 
by plate reading. After that, 1 min at 95°C, 1 min at 55°C, followed by melt curve 
conditions of 65°C, 95°C with increment of 0.5ºC for 5 s, followed by final plate 
reading. GAPDH served as an internal control for sample normalization, and the 
comparative cycle threshold Ct method was used for data quantification. The 
following primer sequences were used in the present study:  
TNFα:  Fwd 5´-TGAACTTCGGGGTGATCG-3´ 
Rev 5´-GGGCTTGTCACTCGAGTTTT-3´ 
IL-6:  Fwd 5´-CCTGGAGTTTGTGAAGAACAACT-3´ 
Rev 5´-GGAAGTTGGGGTAGGAAGGA-3´ 
IL-1β:   Fwd 5´-TGTGATGAAAGACGGCACAC-3´ 
Rev 5´-CTTCTTCTTTGGGTATTGTTTGG-3´ 
GAPDH:  Fwd 5´-TGGGAAGCTGGTCATCAAC-3´ 
Rev: 5´- GCATCACCCCATTTGATCTT-3´ 
2.9 Transient transfection and reporter assays 
At 70-80% confluence, cultured BV2 microglia were transfected with 
pGL4.32[luc2P/NF-B-RE/Hygro] vector (Promega, UK), using Fugene 6 (Promega) 
transfection reagent and incubated for 6 h at 37°C. Following transfection, media 
was changed to OPTI-MEM and incubated for a further 8 h. Thereafter, transfected 
cells were treated with thymoquinone (2.5-10 μM) 30 min prior to stimulation with 
LPS (100 ng/ml) for 6 h. At the end of the stimulation, NF-B-mediated gene 
expression was measured with Dual-Glo® luciferase assay kit (Promega), according 
to the manufacturer’s instructions. 
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To carry out the ARE-dependent reporter gene assay, BV2 microglia were seeded 
out and incubated in solid white 96-well at 37°C for 24 h. A transfection cocktail was 
made by diluting ARE vector (pGL4.37 [luc2P/ARE/Hygro]; Promega) at a 
concentration of 1 ng DNA/μl in Fugene 6 transfection reagent. The cocktail was 
incubated at room temperature for 20 min, and 8 μl to each well, followed by 
incubation for 18 h at 37°C. Thereafter, culture medium was changed to OPTI-MEM 
and incubated for 6 h at 37°C. Cells were then treated with thymoquinone 
(2.5-10 μM) and incubated at 37°C for 8 h. Thereafter, ARE-mediated gene 
expression was measured using Dual-Glo luciferase assay kit (Promega), according 
to the manufacturer’s instructions. 
2.10 Nrf2 knockdown: siRNA silencing experiments 
Small interfering RNA (siRNA) targeted at Nrf2 (Santa Cruz Biotechnology) was 
used to knockout Nrf2. BV2 cells were cultured and incubated at 37°C in a 5% CO2 
incubator until 70-80 % confluent. Thereafter, 2 µl Nrf2 siRNA duplex were diluted 
into 100 µl of siRNA transfection medium (Santa Cruz Biotechnology). In a separate 
tube, 2 µl of transfection reagent (Santa Cruz biotechnology) was diluted into 100 µl 
of siRNA transfection medium. The dilutions were mixed gently and incubated for 30 
min at room temperature. Next, cells were incubated in Nrf2 siRNA transfection 
cocktail for 6 h at 37°C. Control BV2 microglia were transfected with control siRNA. 
Following transfection, media was changed in Nrf2 siRNA and control siRNA 
transfected cells to complete media and incubated for a further 18 h. Effects of 
thymoquinone (10 µM) on NO, PGE2, TNFα, IL-1β, IL-6 and ROS production in LPS-
stimulated control siRNA and Nrf2-siRNA-transfected BV2 cells were then 
determined. Transfection efficiency was determined by preparing RNA from both 
control siRNA and Nrf2 siRNA-transfected BV2 cells, and qPCR carried out to 
determine Nrf2 expression. Similar experiments were carried out in AMPK-knockout 
BV2 microglia. 
2.11 Statistical analysis 
Values of all experiments were represented as a mean ± SEM of at least 
3 experiments. Values were compared using one-way ANOVA followed by a 
post-hoc Student Newman-Keuls test. 
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3. Results 
3.1 Thymoquinone treatment did not affect viability of LPS-stimulated BV2 and 
rat primary microglia 
BV2 cells were treated with thymoquinone (2.5-10 µM) in the presence or absence of 
LPS for 24 h, followed by determination of cell viability. Results of LDH assay 
(Figure 2A) show that thymoquinone treatment did not produce toxicity in BV2 cells. 
Similar results were obtained with rat primary microglia treated with thymoquinone 
(2.5-10 µM) (Figure 2B). These data suggest that the compound did not affect cell 
viability at concentrations used in the study. 
3.2 Thymoquinone produced NF-B-mediated inhibition of neuroinflammation  
We investigated the effects of thymoquinone on the release of pro-inflammatory 
cytokines in BV2 microglia following stimulation with LPS (100 ng/ml). Results in 
Figure 3 show that pre-treatment with thymoquinone (2.5, 5 and 10 µM) produced 
significant (p<0.001) and concentration-dependent reduction in the release of TNFα 
(Figure 3A), IL-6 (Figure 3B) and IL-1β (Figure 3C), following stimulation with LPS. 
Also, qPCR experiments in BV2 microglia revealed statistical (p<0.01) and 
concentration-dependent reduction in the mRNA levels of TNFα (Figure 4A), IL-6 
(Figure 4B) and IL-1β (Figure 4C). 
We also tested effects of thymoquinone of the release and mRNA levels of 
pro-inflammatory cytokines in rat primary microglia stimulated with LPS (10 ng/ml). 
Results in Figures 5A-C show that activation of rat primary microglia resulted in 
marked secretion of TNFα, IL-6 and IL-1β. However, pre-treatment with 
thymoquinone (2.5-10 µM) produced a significant (p<0.001) reduction in the release 
of these pro-inflammatory cytokines. Similar to our observations in BV2 microglia, 
mRNA levels of TNFα, IL-6 and IL-1β were reduced by thymoquinone in rat primary 
microglia stimulated with LPS (10 ng/ml) (Figures 6A-C). 
Experiments on other mediators of neuroinflammation revealed that thymoquinone 
produced significant (p<0.05) and concentration-dependent inhibition of PGE2 
production induced by LPS stimulation in BV2 microglia and rat primary microglia 
(Figures 7A and 8A). We further investigated whether the actions of thymoquinone 
on PGE2 production were mediated by COX-2 and observed a similar trend in the 
effects of thymoquinone; western blotting show that thymoquinone pre-treatment 
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resulted in significantly reduced levels of COX-2 protein levels in LPS-activated BV2 
and rat primary microglia (Figures 7B and 8B), thus suggesting that the effects of 
thymoquinone on PGE2 were mediated through inhibition of this enzyme.  
The effects of thymoquinone on nitrite production in LPS-activated microglia are 
shown in Figures 9A and 10A. Stimulation of BV2 cells and rat primary microglia with 
LPS (100 ng/ml and 10 ng/ml, respectively) resulted in marked release of nitrite from 
the cells. However, on treating cells with thymoquinone (2.5-10 µM) prior to LPS, 
nitrite production was significantly (p<0.05) reduced. We also observed that 
thymoquinone (2.5, 5 and 10 µM) significantly (p<0.001) prevented LPS-induced 
increase in iNOS protein levels in BV2 microglia (Figure 9B). In rat primary microglia 
stimulated with LPS (10 ng/ml), significant (P<0.05) reduction in iNOS protein was 
observed following treatment with 5 and 10 µM thymoquinone, but not with 2.5 µM of 
the compound (Figure 10 B). 
Encouraged by the observed marked inhibition of neuroinflammation by 
thymoquinone, we decided to carry out further experiments in BV2 microglia to 
elucidate the role of NF-B activation in its effects. Initially, we used western blotting 
to determine whether thymoquinone would affect the phosphorylation of IB. Our 
results revealed that stimulation of BV2 microglia with LPS (100 ng/ml) resulted in 
marked increase of phospho-IB protein (Figure 11A). In the presence of 2.5 µM of 
thymoquinone, there was a reduction in the level of phospho-IB protein. However, 
this reduction was not statistically significant. On increasing the concentration of 
thymoquinone to 5 and 10 µM, we observed statistically significant (p<0.05) and 
concentration-dependent inhibition of IB phosphorylation. 
Since NF-B activation involves steps culminating in nuclear translocation of the p65 
subunit followed by p65 phosphorylation, acetylation and methylation, DNA binding, 
and gene transcription 35, we next investigated the effects of thymoquinone on 
LPS-induced nuclear translocation of p65 in BV2 microglia, and used western 
blotting and immunofluorescence to show that the compound prevented this step of 
NF-B activation (Figure 11B and 11C). Encouraged by the pronounced effect of 
thymoquinone on nuclear translocation of the p65 subunit, we became interested in 
evaluating whether the compound would affect LPS-induced acetylation of NF-B. 
Figure 11D shows that activation of BV2 microglia produced an increase in acetyl-
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p65 immunostaining. On re-treating cells with thymoquinone (2.5 µM), there was a 
reduction in fluorescence, indicating reduced levels of p65 acetylation. Interestingly, 
on increasing the concentration of thymoquinone to 5 and 10 µM, acetylation of p65 
was hardly detectable. 
We further investigated the modulatory effect of thymoquinone on NF-B DNA 
binding using an ELISA-based DNA binding assay. Analysis of nuclear extracts from 
BV2 microglia revealed that stimulation with LPS increased DNA binding of NF-B, 
when compared with unstimulated cells. On pre-treating cells with thymoquinone 
(2.5, 5 and 10 µM), there was a significant (p<0.01) and concentration-dependent 
reduction in the binding of NF-B to the DNA (Figure 11E).  
In order to establish whether thymoquinone targets NF-B-mediated gene 
transcription, we transfected BV2 cells with NF-B-luciferase reporter plasmid. 
Stimulation of transfected cells with LPS (100 ng/ml) resulted in marked luciferase 
activity (Figure 11F), which was significantly (p<0.001) repressed by thymoquinone 
(2.5-10 µM) in a concentration-dependent manner.  
3.3 Thymoquinone activates the Nrf2/ARE antioxidant mechanism and 
increases HO-1 and NQO-1 protein levels in BV2 microglia 
Encouraged by the results showing antioxidant action of thymoquinone, we aimed to 
further determine whether the compound has any effect on the Nrf2/ARE antioxidant 
protective mechanism. We treated BV2 microglia with thymoquinone and subjected 
nuclear extracts to western blotting. Figure 12A shows that nuclear accumulation of 
Nrf2 protein was significantly elevated in the presence of 2.5, 5 and 10 µM 
thymoquinone. Similarly, immunofluorescence experiments show an increase in 
nuclear staining of Nrf2 in cells treated with thymoquinone (10 µM), when compared 
with untreated cells (Figure 12B). 
We next determined whether thymoquinone would increase DNA binding Nrf2 in BV2 
microglia. As shown in Figure 12C, thymoquinone (2.5-10 µM) treatment induced 
significant (p<0.001) and concentration-dependent increase in the binding of Nrf2 to 
the ARE consensus binding site. We further show that incubation of ARE 
reporter-transfected BV2 cells with thymoquinone (2.5-10 µM) resulted in significant 
increase in luciferase activity, suggesting an increase in ARE transcriptional activity 
(Figure 12D).  
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Binding of Nrf2 to ARE consensus sites in the DNA results in transcription of 
cytoprotective genes such as HO-1 and NQO1. We were therefore interested in 
investigating the potential effects of thymoquinone on protein levels of both HO-1 
and NQO1. Incubation of thymoquinone with BV2 microglia for 12 h produced a 
significant increase in both HO-1 and NQO1 protein levels, when compared to 
untreated cells (Figures 12E and 12F). 
3.4 Inhibition of neuroinflammation by thymoquinone in LPS-stimulated BV2 
microglia is reversed in the presence Nrf2 siRNA and trigonelline 
Having established that thymoquinone inhibits neuroinflammation and produces 
Nrf2/ARE-mediated antioxidant activity in microglia, it became necessary to elucidate 
whether activation of Nrf2/ARE mechanism contributes to the anti-inflammatory 
effect of the compound. This question was asked using two approaches. Firstly, we 
transfected BV2 cells with small interfering RNA (siRNA) specific for Nrf2 to achieve 
gene knockdown, followed by thymoquinone treatment and LPS stimulation. Levels 
of inflammatory mediators were then measured in culture supernatants. In cells 
transfected with control siRNA, treatment with thymoquinone (10 µM) prior to LPS 
stimulation resulted is significant reduction in production of TNFα (Figure 13A), IL-6 
(Figure 13B), IL1β (Figure 13C), nitrite (Figure 13D), and PGE2 (Figure 13E). 
However, in Nrf2 siRNA transfected cells, the inhibitory effect of thymoquinone on 
inflammatory mediator release was significantly reversed, when compared with 
control siRNA-transfected cells. Similarly, we show that the ability of thymoquinone 
(10 µM) to inhibit DNA binding by NF-B was significantly diminished in nuclear 
extracts of Nrf2 siRNA-transfected BV2 microglia (Figure 13F). We used western 
blotting to monitor the efficiency of Nrf2 knockdown and show that in nuclear extracts 
of Nrf2 siRNA transfected cells, protein levels of Nrf2 were markedly reduced 
(Figure 13G). 
Secondly, trigonelline (an Nrf2 inhibitor) was added to BV2 cells 60 min prior to 
treatment with thymoquinone (10 µM) and stimulation with LPS. Analyses of culture 
supernatants show that anti-inflammatory activity of thymoquinone on the release of 
pro-inflammatory mediators was almost completely abolished in the presence of 
trigonelline (100 µM) (Figures 14A-E). Thymoquinone (10 µM) pre-treatment caused 
an inhibition of binding DNA binding by NF-B. In contrast, incubation with 
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trigonelline 1 h prior to thymoquinone treatment did not result in an inhibition of DNA 
binding (Figure 14F).  
4. Discussion 
Studies have suggested that thymoquinone inhibits neuroinflammation in the 
microglia. Alemi et al. reported that the compound inhibited nitrite production from 
mix glia cells stimulated with LPS 27. Similarly, thymoquinone was shown to 
reduce the levels of pro-inflammatory cytokines and chemokines such as IL-6, IL-
12p40/70, CCL12 /MCP-5, CCL2/MCP-1, and G-CSF as well as iNOS in LPS-
stimulated microglia 28. More detailed experiments by Wang et al. (2015) revealed 
that this compound prevented the release of nitrite, PGE2, TNFα and IL-1β from 
LPS-stimulated BV2 microglia. In this report, thymoquinone was also shown to block 
IB-mediated activation of p65 subunit 29. 
In this study, we have also shown that treatment with thymoquinone suppressed the 
release of the pro-inflammatory cytokines TNFα, IL-1β and IL-6. However, unlike 
previous studies on this compound, we have further demonstrated that the reduction 
of LPS-induced production of nitrite and PGE2 by thymoquinone was mediated by 
enzymatic activities of both iNOS and COX-2, respectively. COX-2 has been shown 
to be upregulated in neuroinflammation involving both the neurons and reactive 
microglia 33, 34, and linked to PGE2 production in the activated microglia 34. 
Also, activation of microglia results in elevated expression of iNOS protein which 
mediates excessive production of nitric oxide 35. 
NF-B activation is known to involve steps culminating in nuclear translocation of the 
p65 subunit followed by p65 phosphorylation, acetylation and methylation, DNA 
binding, and gene transcription 32. Further mechanistic studies by us revealed that 
thymoquinone inhibited both IB as well as p65 phosphorylation and nuclear 
translocation following activation of BV2 microglia with LPS. These results are 
consistent with those published by Wang et al. 29. However, in this study we have 
further shown that thymoquinone prevented LPS-induced acetylation of NF-B, 
through inhibition of acetyl-p65 protein. Following acetylation, activated NF-B is 
known to bind to specific DNA sequences in target genes, thereby regulating the 
transcription of genes involved in neuroinflammation, such as the pro-inflammatory 
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cytokines (TNFα, IL-6 and IL-1β), COX-2 and iNOS. Results of this study shows that 
pre-treatment of BV2 microglia with thymoquinone resulted in marked inhibition of 
binding by active NF-B to its consensus site, following LPS stimulation. 
Furthermore, NF-B-mediated gene transcription was inhibited by thymoquinone 
through suppression of luciferase activity in BV2 microglia which were transiently 
transfected with the NF-B-luciferase reporter plasmid and stimulated with LPS. Our 
results suggest that thymoquinone inhibits neuroinflammation in BV2 microglia 
through steps involving IB phosphorylation,  
New findings have linked activation of the antioxidant transcription factor, Nrf2 to 
anti-inflammatory effects via interactions with NF-B 13. Consequently, we carried 
out investigations to determine whether thymoquinone would activate Nrf2, and 
whether Nrf2 activation contributed to its anti-inflammatory activity in the microglia. 
Treatment of BV2 microglia with thymoquinone resulted in increased nuclear 
localisation and DNA binding of Nrf2, as well as enhancing transcriptional activity of 
the antioxidant responsive element (ARE). We also observed an increase in the 
protein levels of HO-1 and NQO1 after treatment with the compound. These results 
suggest that thymoquinone activation of Nrf2 antioxidant mechanism probably 
contributes to the anti-inflammatory activity of thymoquinone in the microglia. Similar 
observations were made in experiments showing that thymoquinone induces HO-1 in 
HaCaT cells through Nrf2/ARE activation 36. We further show that inhibition of 
inflammatory mediator release and DNA binding by NF-B by thymoquinone was 
significantly reversed in the presence of either Nrf2 siRNA or trigonelline (a specific 
inhibitor of Nrf2). Taken together, we propose that thymoquinone inhibits 
neuroinflammation through mechanisms that are dependent on microglial Nrf2 
activation. 
Taken together, our studies show that thymoquinone inhibits NF-B-dependent 
neuroinflammation in BV2 microglia, by targeting antioxidant pathway involving 
activation of Nrf2/ARE signalling. We propose that activation of Nrf2/ARE signalling 
pathway by thymoquinone probably results in inhibition of NF-B-mediated 
neuroinflammation. 
 16 
 
Acknowledgements 
This study received financial support from the 2015/2016 round of University 
Research Fund (International Strategic Partnerships) awarded by University of 
Huddersfield to Dr Olumayokun Olajide. 
Conflicts of interest 
No conflict of interest. 
Author Contributions 
Ravikanth Velagapudi and Asit Kumar contributed equally to this study.
 17 
 
References 
1. K.Z. Bourne, D.C. Ferrari, C. Lange-Dohna, S. Rossner, T.G. Wood, J.R. 
Perez-Polo, Differential regulation of BACE1 promoter activity by nuclear 
factor-B in neurons and glia upon exposure to β-amyloid peptides, J 
Neurosci Res, 85 (2007) 85: 1194–204. 
2. F. Zhang, L. Jiang, Neuroinflammation in Alzheimer's disease, Neuropsychiatr 
Dis Treat, 11 (2015): 243-56. 
3. M. Jana, S. Dasgupta, X. Liu, K. Pahan, Regulation of tumor necrosis factor-α 
expression by CD40 ligation in BV-2 microglial cells, J Neurochem, 80 (2002) 
197–206. 
4. K. Nakajima, Y. Matsushita, Y. Tohyama, S. Kohsaka, T. Kurihara, Differential 
suppression of endotoxin-inducible inflammatory cytokines by nuclear factor 
kappa B (NFB) inhibitor in rat microglia, Neurosci Lett, 401 (2006) 199–202. 
5. N.R. Bhat, D.L. Feinstein, Q. Shen, A.N. Bhat, p38 MAPK-mediated 
transcriptional activation of inducible nitric-oxide synthase in glial cells roles of 
nuclear factors, nuclear factor κB, cAMP response element-binding protein, 
CCAAT/enhance-binding protein-β, and activating transcription factor-2, J Biol 
Chem, 277 (2002) 29584–29592. 
6. Y-Q. Dai, D-Z. Jin, X-Z. Zhu, D-L Lei, Triptolide inhibits COX-2 expression via 
NF kappa B pathway in astrocytes, Neurosci Res, 55 (2006) 154–160. 
7. A.H. Bhat, K.B. Dar, S. Anees, M.A. Zargar, A. Masood, M.A. Sofi, S.A. 
Ganie, Oxidative stress, mitochondrial dysfunction and neurodegenerative 
diseases; a mechanistic insight, Biomed Pharmacother, 74 (2015) 101-110. 
8. C.C. Benz, C. Yau, Ageing, oxidative stress and cancer: paradigms in 
parallax, Nat Rev Cancer, 8 (2008) 875-879. 
9. Y.C. Yang, H.Y. Chou, T.L. Shen, W.J. Chang, P.H. Tai, T.K. Li, 
Topoisomerase II-mediated DNA cleavage and mutagenesis activated by 
nitric oxide underlie the inflammation-associated tumorigenesis, Antioxid 
Redox Signal, 18 (2013) 1129-1140. 
10. N. Chaudhari, P. Talwar, A. Parimisetty, C. Lefebvre d'Hellencourt, P. 
Ravanan, A molecular web: endoplasmic reticulum stress, inflammation, and 
oxidative stress, Front Cell Neurosci, 8 (2014) 213. 
 18 
 
11. A. Rojo, G. McBean, M. Cindric, J. Egea, M.G. López, P. Rada, N. Zarkovic, 
A. Cuadrado, Redox control of microglial function: molecular mechanisms and 
functional significance, Antioxid Redox Signal, 21 (2014) 1766-1801. 
12. L. Qin, F.T. Crews, NADPH oxidase and reactive oxygen species contribute to 
alcohol-induced microglial activation and neurodegeneration, J 
Neuroinflammation 9 (2012) 5. 
13. M. Sandberg, J. Patil, B. D’Angelo, S.G. Weber, C. Mallard, Nrf2-regulation in 
brain health and disease: implication of cerebral inflammation, 
Neuropharmacology, 79 (2014) 298-306. 
14. S. Nair, S.T. Doh, J.Y. Chan, A.N. Kong, L. Cai, Regulatory potential for 
concerted modulation of Nrf2- and Nfkb1-mediated gene expression in 
inflammation and carcinogenesis, Br. J. Cancer, 99 (2008) 2070-2082. 
15. N.G. Innamorato, A.I. Rojo, A.J. Garcia-Yague, M. Yamamoto, M.L. de 
Ceballos, A. Cuadrado, The transcription factor Nrf2 is a therapeutic target 
against brain inflammation. J. Immunol., 181 (2008) 680-689. 
16. O.A. Olajide, A. Kumar, R. Velagapudi, U.P. Okorji, B.L. Fiebich, Punicalagin 
inhibits neuroinflammation in LPS-activated rat primary microglia. Mol Nutr 
Food Res, 58 (2014) 1843-1851.  
17. R. Velagapudi, M. Aderogba, O.A. Olajide, Tiliroside, a dietary glycosidic 
flavonoid, inhibits TRAF-6/NF- B/p38-mediated neuroinflammation in activated 
BV2 microglia, Biochim Biophys Acta, 1840 (2014) 3311-3319. 
18. L.H. Wu, C. Lin, H.Y. Lin, Y.S. Liu, C.Y. Wu, C.F. Tsai, P.C. Chang, W.L. Yeh, 
D.Y. Luh, Naringenin suppresses neuroinflammatory responses through 
inducing suppressor of cytokine signaling 3 expression, Mol Neurobiol., 53 
(2016) 1080 1091. 
19. N. Chehl, G. Chipitsyna, Q. Gong, C.J. Yeo, H.A. Arafat, Anti-inflammatory 
effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer 
cells, HPB (Oxford) 11 (2009) 373–381. 
20. D. Wang, J. Qiao, X. Zhao, T. Chen, D. Guan, Thymoquinone inhibits IL-1β-
induced inflammation in human osteoarthritis chondrocytes by suppressing 
NF-B and MAPKs signaling pathway, Inflammation, 38 (2015) 2235-2241. 
21. J.K. Kundu, L. Liu, J.W. Shin, Y.J. Surh, Thymoquinone inhibits phorbol ester-
induced activation of NF-B and expression of COX-2, and induces 
 19 
 
expression of cytoprotective enzymes in mouse skin in vivo, Biochem Biophys 
Res Commun, 438 (2013) 721-727. 
22. S. Umar, O. Hedaya, A.K. Singh, S. Ahmed, Thymoquinone inhibits TNF-α-
induced inflammation and cell adhesion in rheumatoid arthritis synovial 
fibroblasts by ASK1 regulation, Toxicol Appl Pharmacol, 287 (2015) 299-305. 
23. N.M. Hamdy, R.A. Taha, Effects of Nigella sativa oil and thymoquinone on 
oxidative stress and neuropathy in streptozotocin-induced diabetic rats, 
Pharmacology, 84 (2009) 127–134. 
24. K. Radad, R. Moldzio, M. Taha, W.D. Rausch, Thymoquinone protects 
dopaminergic neurons against MPP+ and rotenone, Phytother. Res, 23 (2009) 
696–700. 
25. A.H. Alhebshi, M. Gotoh, I. Suzuki, Thymoquinone protects cultured rat 
primary neurons against amyloid β-induced neurotoxicity, Biochem Biophys 
Res Commun, 433 (2013) 362-367. 
26. A. Khan, K. Vaibhav, H. Javed, M.M. Khan, R. Tabassum, M.E. Ahmed et al, 
Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of 
mitochondrial dysfunction and oxidative stress, Mol Cell Biochem, 369 (2012) 
55 65. 
27. M. Alemi, F. Sabouni, F. Sanjarian, K. Haghbeen, S. Ansari, Anti-inflammatory 
effect of seeds and callus of Nigella sativa L. extracts on mix glial cells with 
regard to their thymoquinone content, AAPS PharmSciTech, 14 (2013) 160-
167. 
28. E. Taka, E.A. Mazzio, C.B. Goodman, N. Redmon, H. Flores-Rozas, R. 
Reams, S. Darling-Reed, K.F. Soliman, Anti-inflammatory effects of 
thymoquinone in activated BV-2 microglial cells, J Neuroimmunol, 286 (2015) 
5-12. 
29. Y. Wang, H. Gao, W. Zhang, W. Zhang, L. Fang, Thymoquinone inhibits 
lipopolysaccharide-induced inflammatory mediators in BV2 microglial cells, Int 
Immunopharmacol, 26 (2015) 169-173. 
30. U.P. Okorji, R. Velagapudi, A. El-Bakoush, B.L. Fiebich, O.A. Olajide, 
Antimalarial drug artemether inhibits neuroinflammation in BV2 microglia 
through Nrf2 dependent mechanisms, Mol Neurobiol (In Press) 
31. S.A. Onasanwo, R. Velagapudi, A. El-Bakoush, O.A. Olajide, Inhibition of 
neuroinflammation in BV2 microglia by the biflavonoid kolaviron is dependent 
 20 
 
on the Nrf2/ARE antioxidant protective mechanism, Mol Cell Biochem, 414 
(2016) 23-36. 
32. S.C. Gupta, C. Sundaram, S. Reuter, B.B. Aggarwal, Inhibiting NF-
activation by small molecules as a therapeutic strategy, Biochim Biophys 
Acta,1799 (2010) 775-787. 
33. A. Zarghi, S. Arfaei, Selective COX-2 inhibitors: a review of their structure-
activity relationships, Iran. J. Pharm. Res., 10 (2011), 655–683. 
34. S. Sil, T. Ghosh, Role of cox-2 mediated neuroinflammation on the 
neurodegeneration and cognitive impairments in colchicine induced rat model 
of Alzheimer's Disease, J Neuroimmunol., 291 (2016) 115-124. 
35. G.C. Brown, Mechanisms of inflammatory neurodegeneration: iNOS and 
NADPH oxidase, Biochem. Soc. Trans., 35 (2007) 1119–1121. 
36. J. Kundu J, D.H. Kim, J.K. Kundu, K.S. Chun, Thymoquinone induces heme 
oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and 
AMPKα as upstream targets, Food Chem Toxicol., 65 (2014) 18-26.
 21 
 
Figure Legends 
Figure 1 
Structure of thymoquinone 
Figure 2 
Thymoquinone (2.5-10 µM) treatment did not affect the viability of BV2 microglia 
stimulated with LPS for 24 h. 
Figure 3 
Thymoquinone prevented the release of pro-inflammatory cytokines from 
LPS-activated BV2 microglia. BV2 cells were treated with vehicle or thymoquinone 
(2.5-10 µM) for 30 min prior to LPS stimulation for 24 h. Culture supernatants were 
analysed for TNFα (A), IL-6 (B) and IL-1β (C) using mouse ELISA kits. Bar graph 
shows compiled data from three independent experiments expressed as % 
production compared to LPS control (Mean ± SEM; ***p<0.001; one-way ANOVA) 
Figure 4 
Thymoquinone reduced TNF α (a), IL-6 (b) and IL-1β (C) mRNA levels in 
LPS-activated BV2 microglia. Cells were stimulated with LPS (100 ng/mL) in the 
presence or absence of thymoquinone (2.5–10 μM) for 4 h. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
**p<0.01, ***p<0.001 in comparison with LPS control. 
Figure 5 
Thymoquinone prevented the release of pro-inflammatory cytokines from LPS 
activated rat primary microglia. Microglia cells were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (10 ng/ml) stimulation for 24 h. 
Culture supernatants were analysed for TNFα (A), IL-6 (B) and IL-1β (C) using rat 
ELISA kits. All values are expressed as mean ± SEM for three independent 
experiments. Data were analysed using one-way ANOVA for multiple comparison 
with post-hoc Student Newman-Keuls test, ***p<0.001 in comparison with LPS 
control. 
Figure 6 
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Thymoquinone reduced TNF α (A), IL-6 (B) and IL-1β (C) mRNA levels in 
LPS-activated rat primary microglia. Cells were stimulated with LPS (10 ng/ml) in the 
presence or absence of thymoquinone (2.5–10 μM) for 4 h. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
**p<0.01, ***p<0.001 in comparison with LPS control. 
Figure 7 
Thymoquinone produced COX-2-mediated inhibition of PGE2 production in 
LPS-stimulated BV2 microglia. (A) BV2 cells were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (100 ng/ml) stimulation for 24 h. 
Culture supernatants were analysed for PGE2 production. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
***p<0.001 in comparison with LPS control. (B) BV2 cells were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (100 ng/ml) stimulation for 24 h. 
Cell lysates were analysed using immunoblotting for COX-2 and actin. 
Representative blots and densitometric analyses of three independent experiments 
are shown (Mean ± SEM; **p<0.01, ***p<0.001; one-way ANOVA with post-hoc 
Newman-Keuls test).  
Figure 8 
Thymoquinone produced COX-2-mediated inhibition of PGE2 production in 
LPS-stimulated rat primary microglia. (A) Cells were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (10 ng/ml) stimulation for 24 h. 
Culture supernatants were analysed for PGE2 production. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
***p<0.001 in comparison with LPS control. (B) Primary microglia cells were treated 
with vehicle or thymoquinone (2.5-10 µM) for 30 min prior to LPS (10 ng/ml) 
stimulation for 24 h. Cell lysates were analysed using immunoblotting for COX-2 and 
actin. Representative blots and densitometric analyses of three independent 
experiments are shown (Mean ± SEM; ***p<0.001; one-way ANOVA with post-hoc 
Newman-Keuls test).  
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Figure 9 
Thymoquinone produced iNOS-mediated inhibition of nitrite production in LPS 
stimulated BV2 microglia. (A) BV2 cells were treated with vehicle or thymoquinone 
(2.5-10 µM) for 30 min prior to LPS (100 ng/ml) stimulation for 24 h. Culture 
supernatants were analysed for nitrite production. All values are expressed as mean 
± SEM for three independent experiments. Data were analysed using one-way 
ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
***p<0.001 in comparison with LPS control. (B) BV2 cells were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (100 ng/ml) stimulation for 24 h. 
Cell lysates were analysed using immunoblotting for iNOS and actin. Representative 
blots and densitometric analyses of three independent experiments are shown 
(Mean ± SEM; ***p<0.001; one-way ANOVA with post-hoc Newman-Keuls test).  
Figure 10 
Thymoquinone produced iNOS-mediated inhibition of nitrite production in LPS 
stimulated rat primary microglia. (A) Primary microglia were treated with vehicle or 
thymoquinone (2.5-10 µM) for 30 min prior to LPS (10 ng/ml) stimulation for 24 h. 
Culture supernatants were analysed for nitrite production. All values are expressed 
as mean ± SEM for three independent experiments. Data were analysed using one-
way ANOVA for multiple comparison with post-hoc Student Newman-Keuls test, 
***p<0.001 in comparison with LPS control. (B) Primary microglia were treated with 
vehicle or thymoquinone (2.5-10 µM) for 30 min prior to LPS (10 ng/ml) stimulation 
for 24 h. Cell lysates were analysed using immunoblotting for iNOS and actin. 
Representative blots and densitometric analyses of three independent experiments 
are shown (Mean ± SEM; *p<0.05, ***p<0.001; one-way ANOVA with post-hoc 
Newman-Keuls test).  
Figure 11 
Inhibition of neuroinflammation by thymoquinone is mediated by targeting NF-B 
signalling. (A) BV2 cells were treated with vehicle or thymoquinone (2.5-10 µM) for 
30 min prior to LPS stimulation for 24 h. Cell lysates were analysed using 
immunoblotting for phospho-IB and actin. Representative blots and densitometric 
analyses of three independent experiments are shown (Mean ± SEM; *P<0.05, 
**p<0.01; one-way ANOVA with post-hoc Newman-Keuls test). (B) Thymoquinone 
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reduced phosphorylation of p65 sub-unit in LPS-activated BV2 microglia. BV2 cells 
were treated with thymoquinone (2.5-10 µM) prior to stimulation with LPS for 1 h. 
Cell lysates were analysed using immunoblotting for phospho-p65 and actin. 
Representative blots and densitometric analyses of three independent experiments 
are shown (Mean ± SEM; **p<0.01; one-way ANOVA with post-hoc Newman-Keuls 
test). (C) Thymoquinone prevented nuclear localisation of p65 subunit in LPS-
stimulated BV2 microglia. BV2 cells were treated with thymoquinone (2.5-10 µM) 
prior to LPS (100 ng/ml) for 1 h. Immunofluorescence experiments were carried out 
to detect p65 protein localisation using an anti-p65 antibody and Alexa Fluor 488-
conjugated donkey anti-rabbit IgG antibody. Cells were counterstained with DAPI 
and fluorescence images acquired with an EVOS® FLoid® cell imaging station 
(scale bar: 100 µm). (D) Thymoquinone inhibited acetyl-p65 protein expression in 
LPS-stimulated BV2 microglia. BV2 cells were treated with thymoquinone (2.5-
10 µM) prior to LPS (100 ng/ml) for 1 h. Immunofluorescence experiments were 
carried out to detect p65 protein localisation using an anti-acetyl-p65 antibody and 
Alexa Fluor 488-conjugated donkey anti-rabbit IgG antibody. Cells were 
counterstained with DAPI and fluorescence images acquired with an EVOS® FLoid® 
cell imaging station (scale bar: 100 µm). (E) Thymoquinone inhibited DNA binding of 
NF-B in LPS-stimulated BV2 microglia. Nuclear extracts from cells were added to 
96-well plates to which an oligonucleotide containing the NF-B consensus site (5’-
GGGACTTTCC-3’) has been immobilised, followed by addition of NF-B and HRP-
conjugated antibodies. Absorbance was read in a microplate reader. (Mean ± SEM; 
*P<0.05, **p<0.01; one-way ANOVA with post-hoc Newman-Keuls test). (F) 
Thymoquinone supressed NF-B luciferase activity in BV2 cells transfected with 
pGL4.32 [luc2P/NF-B-RE/Hygro] vector and stimulated with LPS (100 ng/ml) in the 
absence or presence of thymoquinone (2.5-10 µM) for 6 h. (Mean ± SEM; ***p<0.01; 
one-way ANOVA with post-hoc Newman-Keuls test). 
Figure 12 
Thymoquinone activates the Nrf2/ARE antioxidant mechanism in BV2 microglia. (A) 
BV2 cells were treated with vehicle or thymoquinone (2.5-10 µM) for 12 h. Nuclear 
extracts were analysed using immunoblotting for Nrf2 and lamin B. Representative 
blots and densitometric analyses of three independent experiments are shown 
(Mean ± SEM; *p<0.05, **p<0.01; one-way ANOVA with post-hoc Newman-Keuls 
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test). (B) BV2 cells were treated with vehicle or thymoquinone (2.5-10 µM) for 12 h. 
Immunofluorescence experiments were carried out to detect Nrf2 protein localisation 
in the nucleus using an anti-Nrf2 antibody and Alexa Fluor 488-conjugated donkey 
anti-rabbit IgG antibody. Cells were counterstained with DAPI and fluorescence 
images acquired with an EVOS® FLoid® cell imaging station (scale bar: 100 µm). 
(C) Thymoquinone increased binding of Nrf2 to ARE consensus sites in BV2 
microglia. Nuclear extracts from cells were added to 96-well plates to which an 
oligonucleotide containing the ARE consensus site (5’ 
GTCACAGTGACTCAGCAGAATCTG-3’) has been immobilised, followed by addition 
of Nrf2 and HRP-conjugated antibodies. Absorbance was read in a microplate 
reader. (Mean ± SEM; **p<0.01, ***p<0.001; one-way ANOVA with post-hoc 
Newman-Keuls test). (D) Thymoquinone increased ARE luciferase activity in BV2 
cells transfected with pGL4.37 [luc2P/ARE/Hygro] vector and treated with 
thymoquinone (2.5-10 µM) for 6 h. (Mean ± SEM; ***p<0.01; one-way ANOVA with 
post-hoc Newman-Keuls test). (E) Protein levels of HO-1 are increased by 
thymoquinone (2.5-10 µM) incubated with BV2 microglia for 12 h. Cell lysates were 
analysed using immunoblotting for HO-1 and actin. Representative blots and 
densitometric analyses of three independent experiments are shown (Mean ± SEM; 
*p<0.05, ***p<0.001; one-way ANOVA with post-hoc Newman-Keuls test). (F) 
Protein levels of NQO1 are increased by thymoquinone (2.5-10 µM) incubated with 
BV2 microglia for 12 h. Cell lysates were analysed using immunoblotting for NQO1 
and actin. Representative blots and densitometric analyses of three independent 
experiments are shown (Mean ± SEM; **p<0.01, ***p<0.001; one-way ANOVA with 
post-hoc Newman-Keuls test). 
Figure 13 
Inhibition of neuroinflammation by thymoquinone is dependent on Nrf2. Control 
siRNA- and Nrf2 siRNA-transfected BV2 cells were pre-treated with thymoquinone 
(10 μM) prior to stimulation with LPS (100 ng/ml) for 24 h. Culture supernatants were 
analysed for TNFα (A), IL-6 (B), IL-1β (C), nitrite (D) and PGE2 (E). In (F) nuclear 
extracts from cells were added to 96-well plates to which an oligonucleotide 
containing the NF-B consensus site (5’-GGGACTTTCC-3’) has been immobilised, 
followed by addition of NF-B and HRP-conjugated antibodies. Absorbance was 
read in a microplate reader. (G) Western blot experiments on nuclear extracts to 
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determine knockout efficiency. (Mean ± SEM; **p<0.01, ***p<0.001 compared with 
LPS in control siRNA-transfected cells; #p<0.05, ###p<0.001 compared with 
thymoquinone + LPS treatment in control siRNA-transfected cells; one-way ANOVA 
with post-hoc Newman-Keuls test). 
Figure 14 
Inhibition of neuroinflammation by thymoquinone was abolished in the presence of 
trigonelline. BV2 cells were treated with trigonelline (100 µM), followed by 
thymoquinone (10 µM) and LPS (100 ng/ml) for 24 h. Culture supernatants were 
collected and analysed for TNFα (A), IL-6 (B), IL-1β (C), nitrite (D) and PGE2 (E). In 
(F) nuclear extracts from cells were added to 96-well plates to which an 
oligonucleotide containing the NF-B consensus site (5’-GGGACTTTCC-3’) has 
been immobilised, followed by addition of NF-B and HRP-conjugated antibodies. 
Absorbance was read in a microplate reader. (Mean ± SEM; **p<0.01, ***p<0.001 
compared with LPS stimulation; #p<0.05, ##p<0.01, ###p<0.001 compared with 
thymoquinone + LPS treatment; one-way ANOVA with post-hoc Newman-Keuls 
test). 
